Your Complete Guide to Global Clinical Research and GCP Compliance
Sustainable & Green R&D Practices in Practice: Case Studies, Workflows and Governance Models Sustainable & Green R&D Practices in Practice: Case Studies, Workflows and Governance Models In an era increasingly defined by environmental concerns and the push for sustainable development, the pharmaceutical industry finds itself at a crossroads. The necessity for innovation in research and…
High-Impact Sustainable & Green R&D Practices Tactics That De-Risk Clinical Development High-Impact Sustainable & Green R&D Practices Tactics That De-Risk Clinical Development In the evolving landscape of clinical development, especially within the context of ICH-GCP, it is increasingly imperative for pharmaceutical professionals to integrate sustainable and green practices into their research and development (R&D) strategies….
Integrating Sustainable & Green R&D Practices With Clinical Development, CMC and Market Access Integrating Sustainable & Green R&D Practices With Clinical Development, CMC and Market Access In the rapidly evolving landscape of pharmaceutical research and development (R&D), there is an increasing emphasis on sustainable and environmentally friendly practices. The integration of these sustainable practices into…
AI, ML and Automation Use-Cases That Unlock Value in Rare/Ultra-Rare Development Models AI, ML and Automation Use-Cases That Unlock Value in Rare/Ultra-Rare Development Models The development of treatments for rare and ultra-rare diseases presents unique challenges and opportunities within clinical research. Unveiling the potential of Artificial Intelligence (AI), Machine Learning (ML), and automation can significantly…
Risk Management and Stage-Gate Governance for Rare/Ultra-Rare Development Models Risk Management and Stage-Gate Governance for Rare/Ultra-Rare Development Models The landscape of pharmaceutical R&D has undergone significant transformation, particularly in the realm of rare and ultra-rare disease development. With an increasing number of organizations venturing into these niches, understanding the intricacies of risk management and effective…
Read More “Risk Management and Stage-Gate Governance for Rare/Ultra-Rare Development Models” »
IP, Exclusivity and Deal-Making Implications of Strong Rare/Ultra-Rare Development Models Understanding Rare and Ultra-Rare Diseases Rare and ultra-rare diseases, defined as conditions affecting fewer than 200,000 and 1,000 individuals respectively in the US, present unique challenges in clinical trials and drug development. These diseases often lack sufficient epidemiological data, making it difficult to establish effective…
Sustainability, ESG and Green R&D Considerations in Rare/Ultra-Rare Development Models Sustainability, ESG and Green R&D Considerations in Rare/Ultra-Rare Development Models The pharmaceutical and biotechnology sectors face unique challenges in developing treatments for rare and ultra-rare diseases. As we move towards a more sustainable future, integrating Environmental, Social, and Governance (ESG) principles into research and development…
Read More “Sustainability, ESG and Green R&D Considerations in Rare/Ultra-Rare Development Models” »
Roadmap: 12–24 Month Plan to Upgrade Your Organization’s Rare/Ultra-Rare Development Models Roadmap: 12–24 Month Plan to Upgrade Your Organization’s Rare/Ultra-Rare Development Models The development of therapies for rare and ultra-rare diseases presents unique challenges and opportunities for pharmaceutical companies and clinical research organizations. This step-by-step tutorial guide offers a comprehensive roadmap to modernize your organization’s…
How Rare/Ultra-Rare Development Models Supports Precision Medicine and Biomarker-Driven Trials The landscape of pharmaceutical research and development has undergone significant transformation in recent years, especially in the realm of rare and ultra-rare diseases. Precision medicine, fueled by advancements in biomarker discovery, is now an attainable goal, providing a pathway to innovative therapeutic solutions. This article…
Emerging Science and Technology Trends Redefining Rare/Ultra-Rare Development Models In the ever-evolving landscape of pharmaceutical research and development, significant advancements are being made in the approach to rare and ultra-rare disease clinical trials. This article delves into emerging science and technology trends that are redefining the development models associated with day 1 labs clinical trials,…
Read More “Emerging Science and Technology Trends Redefining Rare/Ultra-Rare Development Models” »